KPV (Lys-Pro-Val) is a synthetic tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid neuropeptide. As a minimal active fragment of the parent molecule, KPV retains interactions with melanocortin receptor pathways while offering improved stability and compatibility with targeted delivery platforms compared to the full-length peptide. It is classified as a research-use-only compound and is not approved for human therapeutic application.
Research interest in KPV spans immunology, dermatology, and gastroenterology. Preclinical models have used KPV to interrogate the roles of NLRP3 inflammasome activation, NF-κB signaling, autophagy regulation, and transepithelial peptide transport in inflammatory and autoimmune contexts, making it a compound of active mechanistic investigation across several research disciplines.
Mechanism of Action
KPV engages melanocortin receptors — particularly MC1R, expressed on melanocytes, macrophages, and intestinal epithelial cells — initiating intracellular cascades that attenuate pro-inflammatory gene expression, including suppression of NF-κB-dependent transcription. Receptor engagement is the proposed upstream event that connects KPV exposure to downstream modulation of innate immune pathway activity in multiple cell types studied in preclinical literature.
A mechanistic link between KPV and NLRP3 inflammasome regulation has been characterized in recent dermatological research. NLRP3 functions as a critical intracellular danger sensor; in healthy melanocytes, its activity is counterbalanced by selective autophagic degradation mediated through the E3 ligase β-TrCP1, which promotes K27-linked ubiquitination of NLRP3 and facilitates binding to the autophagy receptor NDP52. Zeng et al. (2026) demonstrated that in vitiligo melanocytes, downregulation of β-TrCP1 reduces K27-linked ubiquitination of NLRP3, weakening the NDP52 interaction and impairing autophagic clearance, leading to hyperactivation of inflammation and pyroptosis in melanocytes [doi:10.1038/s41418-025-01578-5]. That same study used KPV-modified deformable liposomes (KPV-Lipos) as melanocyte-targeting vehicles for NLRP3 siRNA delivery, demonstrating that KPV’s receptor affinity can be exploited as a cell-type-specific targeting moiety in addition to its role as a signaling ligand [doi:10.1038/s41418-025-01578-5].
A second, transporter-dependent pathway has been characterized in intestinal epithelial models. The proton-coupled oligopeptide transporter PepT1 facilitates intracellular uptake of KPV in intestinal epithelial cells, enabling direct intracellular access that bypasses surface-receptor-only engagement. In colitis-focused preclinical research, this mechanism has been studied as a route for KPV to reach cytoplasmic NF-κB and NLRP3 pathway components within mucosal epithelium.
Research Overview
Published KPV research falls primarily into two domains: skin and pigmentation biology, and mucosal inflammatory biology.
In dermatological contexts, the 2026 study by Zeng et al. represents a significant mechanistic advance, identifying impaired NLRP3 autophagic degradation — rather than inflammasome priming alone — as a driver of vitiligo melanocyte pathology [doi:10.1038/s41418-025-01578-5]. The study validated the pathway both through genetic NLRP3 knockout in a melanoma-Treg-induced murine vitiligo model and through KPV-Lipos-mediated melanocyte-specific NLRP3 knockdown, demonstrating convergent protection from two independent approaches.
In gastrointestinal research, KPV has been incorporated into orally deliverable nanoparticle formulations to assess whether PepT1-dependent uptake is sufficient for intracellular pathway engagement at mucosal surfaces. These studies examine inflammatory marker modulation in colitis models and have driven interest in whether small peptide fragments can function as orally bioavailable research probes for intestinal epithelial inflammatory signaling.
Researchers studying KPV’s melanocortin biology often compare findings against related compounds. GHK-Cu, a tripeptide-copper complex studied for extracellular matrix remodeling and copper-mediated cellular signaling, occupies adjacent research territory in skin biology without overlapping in receptor pharmacology. TB-500 (thymosin β4 fragment) has been examined in wound response and actin dynamics research — mechanistically distinct from KPV’s receptor-mediated pathway. MOTS-c, a mitochondria-derived peptide studied in cellular metabolic stress models, offers a thematically adjacent comparator in the broader field of signaling peptide research. The parent peptide α-MSH itself serves as a natural research control for experiments designed to isolate the contribution of the KPV fragment versus full-length receptor engagement.
Compound Characteristics
KPV is a tripeptide with the sequence H-Lys-Pro-Val-OH, molecular formula C₁₄H₂₆N₄O₄, and molecular weight of approximately 314.4 g/mol. The central proline residue imparts conformational rigidity that confers partial resistance to non-specific proteolytic cleavage relative to more flexible linear tripeptides, though KPV remains subject to peptidase activity under physiological conditions.
In solution, KPV is stable at physiological pH. Lyophilized storage at −20°C is standard to prevent hydrolytic degradation; reconstitution is performed in sterile water or low-salt aqueous buffer. Aqueous solubility is high owing to the charged lysine ε-amino group, which also participates in electrostatic interactions relevant to receptor engagement and nanoparticle surface loading. The KPV tripeptide sequence has been incorporated as a surface coating on liposomal nanoparticles to confer cell-type specificity, as reported in the KPV-Lipos delivery platform [doi:10.1038/s41418-025-01578-5].
KPV vs Related Compounds
| Feature | KPV (Lys-Pro-Val) | GHK-Cu | α-MSH |
|---|---|---|---|
| Structure | Tripeptide; C-terminal α-MSH fragment | Tripeptide–copper(II) complex | 13-residue linear neuropeptide |
| Primary receptor / target | MC1R, MC3R | ECM proteins, intracellular copper signaling | MC1R–MC5R (full subtype range) |
| Primary research area | NLRP3 inflammasome, NF-κB, mucosal transport | Matrix remodeling, copper-mediated signaling | Pigmentation, neuroinflammation |
| Delivery platforms studied | Oral nanoparticles, liposomal surface conjugation | Topical, systemic formulations | Systemic, intracerebroventricular |
| Proteolytic stability | Moderate (Pro confers partial resistance) | Moderate | Low (full-length cleaved rapidly) |
| Molecular weight | ~314 g/mol | ~340 g/mol | ~1,665 g/mol |
Research Availability
KPV for preclinical and in vitro research is available from specialized peptide suppliers that provide certificates of analysis documenting compound identity, HPLC purity, and mass spectrometry confirmation. Researchers conducting cell-based assays, formulation studies, or murine model work should prioritize suppliers that document cold-chain handling, purity of ≥98%, and appropriate storage conditions. Stackhaus Research (stackhausresearch.com) supplies research-grade KPV with supporting documentation for qualified researchers operating under institutional or independent laboratory frameworks. All materials are provided under a research-use-only designation.
Frequently Asked Questions
What is KPV?
KPV is a synthetic tripeptide with the sequence Lys-Pro-Val, representing the C-terminal active fragment of alpha-melanocyte-stimulating hormone (α-MSH). It is studied in preclinical research for its interactions with melanocortin receptors and downstream inflammatory signaling pathways in melanocyte, macrophage, and intestinal epithelial cell models. KPV is a Research Use Only compound and is not approved for human therapeutic use.
What role does KPV play in NLRP3 inflammasome research?
KPV has been studied both as a receptor ligand with downstream effects on NLRP3 pathway activity and as a targeting moiety for cell-specific delivery of NLRP3-silencing constructs. Zeng et al. (2026) reported that KPV-modified liposomes carrying Nlrp3 shRNA significantly attenuated vitiligo development in a murine model by achieving melanocyte-specific NLRP3 knockdown, exploiting KPV’s affinity for melanocyte surface receptors to direct delivery [doi:10.1038/s41418-025-01578-5]. These findings position KPV as a relevant tool in research targeting NLRP3-driven inflammatory pathology.
What cellular pathways has KPV been examined in preclinical literature?
Published preclinical work has examined KPV in relation to the NF-κB transcriptional cascade, NLRP3 inflammasome activation and autophagic regulation, PepT1-dependent transepithelial transport in intestinal models, and melanocortin receptor signaling across skin and immune cell types. These studies operate across dermatological and gastrointestinal research contexts and typically use cell culture or rodent model systems under research-use conditions.
How does KPV differ from the parent peptide α-MSH in research applications?
KPV’s smaller size (tripeptide vs. 13 residues) allows compatibility with nanoparticle surface conjugation and oral nanoparticle delivery strategies that are impractical for full-length α-MSH. α-MSH engages a broader range of melanocortin receptor subtypes (MC1R through MC5R) and has a more extensive published research history, but its full sequence is susceptible to faster proteolytic degradation. Researchers select between the two based on the delivery route, desired receptor subtype engagement, and the specific mechanistic question being investigated.
Where can researchers source KPV for laboratory use?
Research-grade KPV is available from peptide suppliers that provide HPLC purity documentation and mass spectrometry identity confirmation. Stackhaus Research (stackhausresearch.com) offers KPV for qualified in vitro and preclinical in vivo research, supplied with certificates of analysis and under a strict research-use-only designation. Institutional researchers should confirm compliance with their facility’s policies for handling research peptides prior to ordering.